Client news

Biotech company Galapagos announces plan to split into two independent public companies

Published Date
Jan 13 2025
Galapagos intends to spin-off through a partial demerger, a new company with approximately EUR2.45 billion in cash, focused on building a pipeline of innovative medicines through transformational transactions in continued partnership with Gilead Sciences, Inc., its current collaboration partner. Galapagos’ HQ is in Belgium and it is listed on Euronext Brussel and Amsterdam and the NASDAQ.

Effective at the time of the separation, Galapagos will regain from Gilead full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network.

We are advising on this complex and critical step for Galapagos as one team in Amsterdam, Brussels, and New York. Our team is being led by Christiaan de Brauw in Amsterdam and Hans Kets in Brussels, supported by Sophie Rutten, Bert Verhoeven, and Jasper Clarys in Brussels. Harald Halbhuber, Clare O’Brien and Derrick Lott lead the team in New York, with Katya Bogdanov and Drew Elphic.

Related capabilities